ReviewMolecular medicine (Cambridge, Mass.)2021
Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease.
Review in Molecular medicine (Cambridge, Mass.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Alpha-Synuclein Strain Variability in Body-First and Brain-First Synucleinopathies.Frontiers in aging neuroscience · 2022Pooled it
- A review of FDG-PET biomarker analysis methods in Parkinson's disease.Journal of Parkinson's disease · 2026Review
- Biological heterogeneity in Parkinson's disease: implications for MRI-based patient stratification.NPJ Parkinson's disease · 2026Review
- Discordance Between Striatal Dopaminergic Imaging and Motor Performances in REM Sleep Behavior Disorder.Neurology open access · 2026Article
- Narrative Review of Body-First Versus Brain-First Prodromal Neuropsychiatric Symptoms in Parkinson's Disease.Cureus · 2026Review
- Comparison of clinical features and cerebral glucose metabolism between patients with major depressive disorder and Parkinson's with depression.BMC psychiatry · 2026Article
- Brain metabolic and network profiles characterized by comorbid depressive symptoms and sleep disturbances in Parkinson's disease: anFrontiers in aging neuroscience · 2026Article
- Integrative multi-omics and network-based machine learning for early diagnosis of Parkinson's disease.PloS one · 2026Article
- Parkinson's Disease: The Epidemiology, Risk Factors, Molecular Pathogenesis, Prevention, and Therapy.MedComm · 2025Review
- Cerebellar large-scale network connectivity in Parkinson's disease: associations with emotion, cognition, and aging effects.Brain imaging and behavior · 2025Article
- Midbrain and pallidal iron changes identify patients with REM sleep behaviour disorder and Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Presynaptic terminal integrity is associated with glucose metabolism in Parkinson's disease.European journal of nuclear medicine and molecular imaging · 2025Article
- Parkinson's disease and glucose metabolism impairment.Translational neurodegeneration · 2025Review
- Hot Topics and Frontiers of Resting-State fMRI in Parkinson's Disease: Research Trends and Paradigm Shifts From a Bibliometric Perspective.Parkinson's disease · 2025Review
- Impaired Striatum Dopamine Release in Parkinson's Disease.Current medicinal chemistry · 2025Article
- Parkinson's disease cerebrovascular reactivity pattern: A feasibility study.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024Article
- The value of PET/CT in the diagnosis and differential diagnosis of Parkinson's disease: a dual-tracer study.NPJ Parkinson's disease · 2024Article
- Association of synuclein alpha (Quantitative imaging in medicine and surgery · 2024Article
- Evaluation of damage discrimination in dopaminergic neurons using dopamine transporter PET tracer [EJNMMI research · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) commences several years before the onset of motor features. Pathophysiological understanding of the pre-clinical or early prodromal stages of PD are essential for the development of new therapeutic strategies. Two categories of patients are ideal to study the early disease stages. Idiopathic rapid eye movement sleep behavior disorder (iRBD) represents a well-known prodromal stage of PD in which pathology is presumed to have reached the lower brainstem. The majority of patients with iRBD will develop manifest PD within years to decades. Another category encompasses non-manifest mutation carriers, i.e. subjects without symptoms, but with a known mutation or genetic variant which gives an increased risk of developing PD. The speed of progression from preclinical or prodromal to full clinical stages varies among patients and cannot be reliably predicted on the individual level. Clinical trials will require inclusion of patients with a predictable conversion within a limited time window. Biomarkers are necessary that can confirm pre-motor PD status and can provide information regarding lead time and speed of progression. Neuroimaging changes occur early in the disease process and may provide such a biomarker. Studies have focused on radiotracer imaging of the dopaminergic nigrostriatal system, which can be assessed with dopamine transporter (DAT) single photon emission computed tomography (SPECT). Loss of DAT binding represents an effect of irreversible structural damage to the nigrostriatal system. This marker can be used to monitor disease progression and identify individuals at specific risk for phenoconversion. However, it is known that changes in neuronal activity precede structural changes. Functional neuro-imaging techniques, such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.